Therefore, our study explored the role of EGFR inhibitors (afatinib and allitinib) and conducted a comprehensive in vitro and in silico analysis of the molecular mechanisms triggered by KRAS mutations in a panel of lung cancer cell lines. The gene discussed is EGFR; the disease is lung cancer.